Skip to content

Study · Animal study (in vivo) · mouse and rat · 2011

7 results

Coadministration of epidermal growth factor and growth hormone releasing peptide-6 improves clinical recovery in experimental autoimmune encephalitis.

del Barco DG, Montero E, Coro-Antich RM, Brown E, Suarez-Alba J, Lopez L, Subirós N, Berlanga J

Restorative neurology and neuroscience1 Jan 2011Cited by 14 (Europe PMC)

PMID21697595 (opens in a new tab)DOI10.3233/rnn-2011-0595 (opens in a new tab)PepBankPUB-21697595
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with mild EAE, GHRP‑6 alone did not reduce the clinical score, whereas the EGF combination did.

    In plain wordsIn rats with mild EAE, GHRP‑6 alone did not reduce the clinical score.

    Peptide
    GHRP-6
    Outcome
    No significant changeClinical score in mild EAE
    Study

    ratn: not reported in source

    experimental autoimmune encephalitis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Only the combined EGF+GHRP(6) therapy reduced the clinical score in mild as well in severe EAE forms.
    1 context sentence
    Summary · context
    Mild and severe forms of EAE were generated immunizing rats and mice with xenogeneic spinal cord homogenate and with the encephalitogenic peptide MOG(p35-35), respectively. EGF and GHRP(6) alone or combined were administered in therapeutic and prophylactic schedules.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with severe EAE, GHRP‑6 alone did not reduce the clinical score, whereas the EGF combination did.

    In plain wordsIn mice with severe EAE, GHRP‑6 alone did not reduce the clinical score.

    Peptide
    GHRP-6
    Outcome
    No significant changeClinical score in severe EAE
    Study

    mousen: not reported in source

    experimental autoimmune encephalitis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Only the combined EGF+GHRP(6) therapy reduced the clinical score in mild as well in severe EAE forms.
    1 context sentence
    Summary · context
    Mild and severe forms of EAE were generated immunizing rats and mice with xenogeneic spinal cord homogenate and with the encephalitogenic peptide MOG(p35-35), respectively. EGF and GHRP(6) alone or combined were administered in therapeutic and prophylactic schedules.

Studies that did not test the peptide alone5

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In rats with mild EAE, only combined EGF and GHRP‑6 therapy reduced the clinical score.

    In plain wordsIn rats with mild EAE, only EGF plus GHRP‑6 reduced the clinical score.

    Peptide
    GHRP-6
    Outcome
    DecreaseClinical score in mild EAE
    Study

    ratn: not reported in source

    experimental autoimmune encephalitis
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Only the combined EGF+GHRP(6) therapy reduced the clinical score in mild as well in severe EAE forms.
    1 context sentence
    Summary · context
    Mild and severe forms of EAE were generated immunizing rats and mice with xenogeneic spinal cord homogenate and with the encephalitogenic peptide MOG(p35-35), respectively. EGF and GHRP(6) alone or combined were administered in therapeutic and prophylactic schedules.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In mice with severe EAE, only combined EGF and GHRP‑6 therapy reduced the clinical score.

    In plain wordsIn mice with severe EAE, only EGF plus GHRP‑6 reduced the clinical score.

    Peptide
    GHRP-6
    Outcome
    DecreaseClinical score in severe EAE
    Study

    mousen: not reported in source

    experimental autoimmune encephalitis
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    Only the combined EGF+GHRP(6) therapy reduced the clinical score in mild as well in severe EAE forms.
    1 context sentence
    Summary · context
    Mild and severe forms of EAE were generated immunizing rats and mice with xenogeneic spinal cord homogenate and with the encephalitogenic peptide MOG(p35-35), respectively. EGF and GHRP(6) alone or combined were administered in therapeutic and prophylactic schedules.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 05AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome

    In mice with severe EAE, EGF plus GHRP‑6 improved survival, reported as nearly 100%.

    In plain wordsIn mice with severe EAE, EGF plus GHRP‑6 improved survival, reported as nearly 100%.

    Peptide
    GHRP-6
    Outcome
    IncreaseSurvival in severe EAE
    Study

    mousen: not reported in source

    experimental autoimmune encephalitis
    Outcome group
    Mortality · Whole body

    Source sentences

    Summary
    The combination also improved the survival rate in nearly 100% of the severe EAE animals.
    1 context sentence
    Summary · context
    Mild and severe forms of EAE were generated immunizing rats and mice with xenogeneic spinal cord homogenate and with the encephalitogenic peptide MOG(p35-35), respectively. EGF and GHRP(6) alone or combined were administered in therapeutic and prophylactic schedules.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 06AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In EAE animals, combined EGF and GHRP‑6 treatment increased brain IGF-1 transcript.

    In plain wordsIn rats and mice with EAE, EGF plus GHRP‑6 increased brain IGF-1 transcript.

    Peptide
    GHRP-6
    Outcome
    IncreaseBrain IGF-1 transcript
    Study

    rats and micen: not reported in source

    experimental autoimmune encephalitis
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    In addition to these effects, there was an increase in the brain IGF-1 transcript and a decrease of serum MDA.
    2 context sentences
    Summary · context
    Only the combined EGF+GHRP(6) therapy reduced the clinical score in mild as well in severe EAE forms. The combination also improved the survival rate in nearly 100% of the severe EAE animals.
    Summary · context
    Mild and severe forms of EAE were generated immunizing rats and mice with xenogeneic spinal cord homogenate and with the encephalitogenic peptide MOG(p35-35), respectively. EGF and GHRP(6) alone or combined were administered in therapeutic and prophylactic schedules.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  5. 07AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In EAE animals, combined EGF and GHRP‑6 treatment decreased serum MDA.

    In plain wordsIn rats and mice with EAE, EGF plus GHRP‑6 decreased blood MDA.

    Peptide
    GHRP-6
    Outcome
    DecreaseSerum MDA
    Study

    rats and micen: not reported in source

    experimental autoimmune encephalitis
    Outcome group
    Inflammation markers · Immune and inflammation

    Source sentences

    Summary
    In addition to these effects, there was an increase in the brain IGF-1 transcript and a decrease of serum MDA.
    2 context sentences
    Summary · context
    Only the combined EGF+GHRP(6) therapy reduced the clinical score in mild as well in severe EAE forms. The combination also improved the survival rate in nearly 100% of the severe EAE animals.
    Summary · context
    Mild and severe forms of EAE were generated immunizing rats and mice with xenogeneic spinal cord homogenate and with the encephalitogenic peptide MOG(p35-35), respectively. EGF and GHRP(6) alone or combined were administered in therapeutic and prophylactic schedules.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.